A
Accession Therapeutics
Developing novel immuno-oncology therapeutics – combining high specificity and potency to counter tumour diversity
About Accession Therapeutics
Accession Therapeutics is a biotechnology startup that operates in the field of immuno-oncology. The company is focused on developing innovative treatments for some of the most challenging and widespread forms of cancer. The business model revolves around the development and commercialization of its proprietary stealth virus platform technology, Trocept, which is designed to target and eradicate all cells in a tumor, regardless of diversity. This technology offers a significant advancement in cancer treatment by eliminating many of the drawbacks of current immunotherapies.
Read full description
The company is led by immuno-oncology pioneer Bent Jakobsen, PhD FMedSci, who is driving the development of a pipeline of highly differentiated products. Accession Therapeutics' first drug candidate is currently at the IND-enabling stage, which means it is being prepared for clinical trials, with these trials planned for 2024. The company plans to follow this with a pipeline of candidates engineered to revolutionize cancer treatment.
Accession Therapeutics' business model is based on the development and eventual commercialization of these innovative cancer treatments. The company's primary clients will be healthcare providers and patients suffering from the types of cancer that its treatments are designed to combat. The company operates in the biotechnology and healthcare markets, which are characterized by high growth potential and significant investment in research and development.
In summary, Accession Therapeutics is a pioneering biotech startup, developing cutting-edge immuno-oncology treatments with the potential to revolutionize cancer care.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Oxford, United Kingdom
- Employees
- 48
- Open positions
- None listed
- Dealroom signal
- 76.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, uk is8 life sciences, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Accession Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Mar 2026 | $8.6M | — | Horizon Europe | ↗ |
| LATE VCOther financing | Dec 2025 | $40M | $161M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Accession Therapeutics is 950 monthly website visits, down 5% over the last three months. Accession Therapeutics's team grew 6.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 OXcanAI-powered liquid biopsy tests for early cancer detection |
Oxford, United Kingdom | Operational | 29 | $19M | $55M |
 Myricx BioNovel antibody-drug conjugate payloads for cancer treatment |
London, United Kingdom | Acquired | |||
 MacomicsDeveloping precision medicines to modulate macrophages for the treatment of cancer |
Edinburgh, United Kingdom | Operational | |||
 Amphista TherapeuticsNext-generation therapeutics for targeted protein degradation |
Great Abington, United Kingdom | Operational | |||
 Leucid BioNext-generation CAR-T cell therapies for refractory cancers |
London, United Kingdom | Operational | |||
 AutolusProgrammed T-cell immunotherapies for cancer and autoimmune diseases |
London, United Kingdom | Operational | |||
 Aurum BiosciencesOxygen carrier therapeutic and diagnostic for stroke |
Glasgow, United Kingdom | Operational | |||
 ElasmogenNext generation therapeutic biologics company discovering and developing drugs |
Aberdeen, United Kingdom | Operational |
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Primavera Capital Group
Birk Venture
Horizon Europe
Series A2 investors entered at this stage
Primary Venture Partners
iGlobe Partners
Other known investors1 additional known investor
Cardiff University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Accession Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Accession Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.